Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 6.

Journal Article

Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen, Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2015). Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128 (12). S. 1562 - 1567. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chen, Robert W., Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Sievers, Eric L. and Younes, Anas (2012). Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Karuturi, Meghan S., Arai, Sally, Chen, Robert W., Gopal, Ajay K., Feng, Lei, Yuan, Ying, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlet, Nancy L., Cheson, Bruce D., Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Fanale, Michelle A., de Vos, Sven, Engert, Andreas, Illidge, Tim, Borchmann, Peter, Morschhauser, Franck, Horning, Sandra J. and Younes, Anas (2012). Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

This list was generated on Wed Apr 24 12:52:20 2024 CEST.